Hormonal therapy for prostate cancer: Toward further unraveling of androgen receptor function

Nima Sharifi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Prostate cancer is a major cause of cancer-related death in men. Prostate cancer is an androgen-responsive tumor and the treatment of advanced prostate cancer involves hormonal therapy. First-line treatment for advanced prostate cancer is androgen deprivation therapy (ADT), usually with agents that suppress gonadotropins through a pituitary mechanism. Gonadotropin-releasing hormone agonists and antagonists both suppress gonadal release of testosterone, although their activity profiles vary. ADT down-regulates androgen receptor (AR) transcriptional activity in the tumor but the response in metastatic disease is transient and tumors eventually progress as castration-resistant prostate cancer (CRPC). Although serum testosterone concentrations decline dramatically with ADT, CRPC growth remains largely dependent on AR activity. Secondary hormonal therapies are then often employed to further dampen AR-driven transcription. These secondary hormonal therapies either further deplete adrenal or intratumoral androgen synthesis, or directly and competitively antagonize AR. New hormonal agents with both of these mechanisms are in clinical trials and show promising activity in patients with CRPC. Abiraterone acetate is an inhibitor of CYP17, which is an enzyme required for the synthesis of all androgens and estrogens. MDV3100 is an AR antagonist that has a higher affinity for AR than any other AR antagonist in clinic use. In phase I and phase II clinical trials, both agents have significant activity. These agents and the promise of the development of others provide hope that more effective hormonal therapies may soon be offered to patients, which will improve clinical outcomes.

Original languageEnglish (US)
Pages (from-to)1046-1051
Number of pages6
JournalAnti-Cancer Agents in Medicinal Chemistry
Volume9
Issue number10
DOIs
StatePublished - 2009

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Androgens
Castration
Androgen Receptor Antagonists
Therapeutics
Testosterone
Neoplasms
Steroid 17-alpha-Hydroxylase
Hormone Antagonists
Phase II Clinical Trials
Gonadotropins
Gonadotropin-Releasing Hormone
Estrogens
Down-Regulation
Clinical Trials
Enzymes
Growth
Serum

Keywords

  • Androgen deprivation
  • Androgen receptor
  • Antagonists
  • Castration-resistance
  • CYP17
  • Hormonal therapy
  • Prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Pharmacology
  • Medicine(all)

Cite this

Hormonal therapy for prostate cancer : Toward further unraveling of androgen receptor function. / Sharifi, Nima.

In: Anti-Cancer Agents in Medicinal Chemistry, Vol. 9, No. 10, 2009, p. 1046-1051.

Research output: Contribution to journalArticle

@article{5753e27242204fe4be861c141d51d6bc,
title = "Hormonal therapy for prostate cancer: Toward further unraveling of androgen receptor function",
abstract = "Prostate cancer is a major cause of cancer-related death in men. Prostate cancer is an androgen-responsive tumor and the treatment of advanced prostate cancer involves hormonal therapy. First-line treatment for advanced prostate cancer is androgen deprivation therapy (ADT), usually with agents that suppress gonadotropins through a pituitary mechanism. Gonadotropin-releasing hormone agonists and antagonists both suppress gonadal release of testosterone, although their activity profiles vary. ADT down-regulates androgen receptor (AR) transcriptional activity in the tumor but the response in metastatic disease is transient and tumors eventually progress as castration-resistant prostate cancer (CRPC). Although serum testosterone concentrations decline dramatically with ADT, CRPC growth remains largely dependent on AR activity. Secondary hormonal therapies are then often employed to further dampen AR-driven transcription. These secondary hormonal therapies either further deplete adrenal or intratumoral androgen synthesis, or directly and competitively antagonize AR. New hormonal agents with both of these mechanisms are in clinical trials and show promising activity in patients with CRPC. Abiraterone acetate is an inhibitor of CYP17, which is an enzyme required for the synthesis of all androgens and estrogens. MDV3100 is an AR antagonist that has a higher affinity for AR than any other AR antagonist in clinic use. In phase I and phase II clinical trials, both agents have significant activity. These agents and the promise of the development of others provide hope that more effective hormonal therapies may soon be offered to patients, which will improve clinical outcomes.",
keywords = "Androgen deprivation, Androgen receptor, Antagonists, Castration-resistance, CYP17, Hormonal therapy, Prostate cancer",
author = "Nima Sharifi",
year = "2009",
doi = "10.2174/187152009789735044",
language = "English (US)",
volume = "9",
pages = "1046--1051",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
issn = "1871-5206",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Hormonal therapy for prostate cancer

T2 - Toward further unraveling of androgen receptor function

AU - Sharifi, Nima

PY - 2009

Y1 - 2009

N2 - Prostate cancer is a major cause of cancer-related death in men. Prostate cancer is an androgen-responsive tumor and the treatment of advanced prostate cancer involves hormonal therapy. First-line treatment for advanced prostate cancer is androgen deprivation therapy (ADT), usually with agents that suppress gonadotropins through a pituitary mechanism. Gonadotropin-releasing hormone agonists and antagonists both suppress gonadal release of testosterone, although their activity profiles vary. ADT down-regulates androgen receptor (AR) transcriptional activity in the tumor but the response in metastatic disease is transient and tumors eventually progress as castration-resistant prostate cancer (CRPC). Although serum testosterone concentrations decline dramatically with ADT, CRPC growth remains largely dependent on AR activity. Secondary hormonal therapies are then often employed to further dampen AR-driven transcription. These secondary hormonal therapies either further deplete adrenal or intratumoral androgen synthesis, or directly and competitively antagonize AR. New hormonal agents with both of these mechanisms are in clinical trials and show promising activity in patients with CRPC. Abiraterone acetate is an inhibitor of CYP17, which is an enzyme required for the synthesis of all androgens and estrogens. MDV3100 is an AR antagonist that has a higher affinity for AR than any other AR antagonist in clinic use. In phase I and phase II clinical trials, both agents have significant activity. These agents and the promise of the development of others provide hope that more effective hormonal therapies may soon be offered to patients, which will improve clinical outcomes.

AB - Prostate cancer is a major cause of cancer-related death in men. Prostate cancer is an androgen-responsive tumor and the treatment of advanced prostate cancer involves hormonal therapy. First-line treatment for advanced prostate cancer is androgen deprivation therapy (ADT), usually with agents that suppress gonadotropins through a pituitary mechanism. Gonadotropin-releasing hormone agonists and antagonists both suppress gonadal release of testosterone, although their activity profiles vary. ADT down-regulates androgen receptor (AR) transcriptional activity in the tumor but the response in metastatic disease is transient and tumors eventually progress as castration-resistant prostate cancer (CRPC). Although serum testosterone concentrations decline dramatically with ADT, CRPC growth remains largely dependent on AR activity. Secondary hormonal therapies are then often employed to further dampen AR-driven transcription. These secondary hormonal therapies either further deplete adrenal or intratumoral androgen synthesis, or directly and competitively antagonize AR. New hormonal agents with both of these mechanisms are in clinical trials and show promising activity in patients with CRPC. Abiraterone acetate is an inhibitor of CYP17, which is an enzyme required for the synthesis of all androgens and estrogens. MDV3100 is an AR antagonist that has a higher affinity for AR than any other AR antagonist in clinic use. In phase I and phase II clinical trials, both agents have significant activity. These agents and the promise of the development of others provide hope that more effective hormonal therapies may soon be offered to patients, which will improve clinical outcomes.

KW - Androgen deprivation

KW - Androgen receptor

KW - Antagonists

KW - Castration-resistance

KW - CYP17

KW - Hormonal therapy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=73349111609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349111609&partnerID=8YFLogxK

U2 - 10.2174/187152009789735044

DO - 10.2174/187152009789735044

M3 - Article

C2 - 19719456

AN - SCOPUS:73349111609

VL - 9

SP - 1046

EP - 1051

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

SN - 1871-5206

IS - 10

ER -